Skyrizi 150 mg/mL single-dose prefilled pen Images
Generic Name: risankizumab
This medication has been identified as Skyrizi 150 mg/mL single-dose prefilled pen. It is supplied by AbbVie Inc.
Skyrizi is used in the treatment of Crohn's Disease; Psoriatic Arthritis; Plaque Psoriasis; Psoriasis and belongs to the drug class interleukin inhibitors. Skyrizi 150 mg/mL single-dose prefilled pen is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Skyrizi
- Generic Name
- risankizumab
- Strength
- 150 mg/mL single-dose prefilled pen
- Availability
- Prescription only
- Drug Class
- Interleukin inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- AbbVie Inc.
- National Drug Code (NDC)
- 00074-2100
More about Skyrizi (risankizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (40)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
